A Phase 3 interventional study of Inhaled Treprostinil and Treprostinil Ultrasonic Nebulizer in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease and Progressive Pulmonary Fibrosis, sponsored by United Therapeutics. Enrolling by invitation at 192 sites in 18 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 2nd largest by planned enrollment of the 188 interventional ones that give a count, is one of 17 that started in 2022, is one of 37 in phase 3, reaches primary completion later than 43 of the 50 other live ones, and was the 163rd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Oorja Bio, Inc. · Sites in United States
Ages 40+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,850 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 85 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Study RIN-PF-302 is a Phase 3, multicenter, open-label extension (OLE) study for eligible subjects who completed Study RIN-PF-301, Study RIN-PF-303, or Study RIN-PF-305 to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Following OLE entry, subjects will return at Week 4, Week 12, and every 12 weeks thereafter for up to 6 years or until the subject prematurely discontinues study treatment due an adverse event (AE)/serious adverse event (SAE) or other reason, inhaled treprostinil becomes commercially available for IPF or PPF, or the study is discontinued by the Sponsor (whichever is sooner).
Efficacy assessments will include spirometry (forced expiratory volume in 1 second [FEV1] and forced vital capacity [FVC]), time to clinical worsening, time to first acute exacerbation of IPF or interstitial lung disease (ILD), overall survival, King's Brief Interstitial Lung Disease (K-BILD) Questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and diffusion capacity of lungs for carbon monoxide (DLCO). Safety assessments will include monitoring for the development of AEs/SAEs, vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters. In addition, up to 24 eligible subjects with IPF rolling over from Study RIN-PF-301 and up to 24 eligible subjects with PPF rolling over from Study RIN-PF-305 may participate in a PK substudy to evaluate the systemic exposure of treprostinil after inhaled administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer
Inhaled Treprostinil (6 mcg/breath) administered QID
Also known as: Tyvaso
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF
Incidence of AEs and SAEs, incidence of abnormal clinical laboratory parameters, abnormal vital signs, and abnormal 12-lead ECGs
Time frame: Baseline to 6 years
Showing the first 100 of 192 sites across 18 countries. Choose a country and city above to see the rest.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2029, 87 months after the start.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 87 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Idiopathic Pulmonary Fibrosis →